Nektar Therapeutics heads into its May 7 first-quarter report carrying two compounding weights: a flurry of securities fraud class actions and a 10.7% weekly price decline that has tested the conviction of a Street that only recently turned bullish on the stock.
The lawsuit angle dominates the news flow this week. Multiple law firms — Rosen, Faruqi & Faruqi, Pomerantz, Levi & Korsinsky, and Bronstein Gewirtz among others — have filed or issued reminders about a securities fraud class action with a lead plaintiff deadline of May 5. The allegation centres on Chief Research and Development Officer Jonathan Zalevsky allegedly overstating enrollment compliance in Nektar's clinical trials. That is a direct attack on the core bull thesis: REZPEG's path through atopic dermatitis trials. The timing, with Q1 results arriving just two days after the lawsuit deadline, makes the earnings call unusually charged.
Short interest tells a more subdued story than the legal headlines might suggest. At 11.0% of free float — down from around 12.1% in late March — shorts have actually been trimming exposure into the stock's April run-up. The official FINRA fortnightly figure puts the figure slightly higher at a settlement-adjusted 11.4% with 5.8 days to cover, but the directional trend is clear: short sellers added during the March weakness and have been scaling back as the price recovered. Borrow availability is wide open. Cost to borrow has edged up 41% on the week to 0.37% but that is still a negligible rate — there is no squeeze pressure here, and the borrow market is not flashing any kind of alarm. The ORTEX short score has also eased materially, falling from 60.2 on April 15 to 51.7 by April 28, a sign that the aggregate short-side indicators are cooling rather than building.
Options positioning has shifted more cautious. The put/call ratio has climbed to 0.59, running well above its 20-day average of 0.38 — about 1.6 standard deviations elevated. Through mid-April the PCR was hugging a low of 0.23-0.28, reflecting strong call-buying momentum. That has now reversed sharply, with protective put demand rising steeply over the past eight sessions. Options traders are clearly hedging into the earnings event and the lawsuit deadline rather than chasing further upside.
The analyst community, however, has been constructive almost without exception. Last week brought a wave of target increases: Citigroup raised its target to $151 (from $123), BTIG lifted to $178 (from $151), and HC Wainwright moved to $185 (from $165). All three maintained Buy ratings. The lone outlier is Wedbush, which holds at Neutral with a $95 target — the only sceptical voice on the panel. The consensus mean target of $144 implies roughly 73% upside to Wednesday's close of $83.20, a wide gap that reflects both genuine optimism about REZPEG's atopic dermatitis data and the market's current discounting of near-term legal and clinical risk. The bull case rests on improved EASI-100 response rates and a 60% probability-of-success estimate for REZPEG in AD with 15% peak market penetration; the bear case points squarely to the developmental risk and the financial losses tied to royalty liability revaluations.
Institutional ownership adds one more layer of interest. FMR (Fidelity) is the largest holder at 9%, having added nearly 2.9 million shares in its most recent reporting period — a sizable conviction build. Two Seas Capital entered with a 5.8% stake, reported as a new position. Vanguard and Invesco also added in the most recent quarter. Against that, Morgan Stanley trimmed 360,000 shares and Susquehanna cut 542,000 — the kind of institutional split that reflects genuine disagreement about where the risk/reward sits.
What to watch is straightforward: the May 5 lead plaintiff deadline establishes whether the securities case gains real legal traction, and the May 7 Q1 earnings call will be the first opportunity for management to address the enrollment compliance allegations directly. How the company responds to the Zalevsky overstating claims — and what it discloses about current trial enrollment status — will define the stock's next move far more than any headline financial figures.
See the live data behind this article on ORTEX.
Open NKTR on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
